Abstract

Mutations in mexZ, encoding a negative regulator of the expression of the mexXY efflux pump genes, are frequently acquired by Pseudomonas aeruginosa at early stages of lung infection. Although traditionally related to resistance to the first-line drug tobramycin, mexZ mutations are associated with low-level aminoglycoside resistance when determined in the laboratory, suggesting that their selection during infection may not be necessarily, or only, related to tobramycin therapy. Here, we show that mexZ-mutated bacteria tend to accumulate inside the epithelial barrier of a human airway infection model, thus colonising the epithelium while being protected against diverse antibiotics. This phenotype is mediated by overexpression of lecA, a quorum sensing-controlled gene, encoding a lectin involved in P. aeruginosa tissue invasiveness. We find that lecA overexpression is caused by a disrupted equilibrium between the overproduced MexXY and another efflux pump, MexAB, which extrudes quorum sensing signals. Our results indicate that mexZ mutations affect the expression of quorum sensing-regulated pathways, thus promoting tissue invasiveness and protecting bacteria from the action of antibiotics within patients, something unnoticeable using standard laboratory tests.

Mutations in mexZ, encoding a negative regulator of efflux pump genes, are frequently acquired by Pseudomonas aeruginosa during early lung infection, but do not confer high antibiotic resistance as measured in lab tests. Here, Laborda et al. show that mexZ mutations affect quorum sensing pathways, thus promoting tissue invasiveness and protecting bacteria from the action of antibiotics within tissues.

Details

Title
Mutations in the efflux pump regulator MexZ shift tissue colonization by Pseudomonas aeruginosa to a state of antibiotic tolerance
Author
Laborda, Pablo 1   VIAFID ORCID Logo  ; Lolle, Signe 2 ; Hernando-Amado, Sara 3   VIAFID ORCID Logo  ; Alcalde-Rico, Manuel 4   VIAFID ORCID Logo  ; Aanæs, Kasper 5 ; Martínez, José Luis 3   VIAFID ORCID Logo  ; Molin, Søren 6 ; Johansen, Helle Krogh 7   VIAFID ORCID Logo 

 Rigshospitalet, Department of Clinical Microbiology 9301, Copenhagen, Denmark (GRID:grid.475435.4); Technical University of Denmark, The Novo Nordisk Foundation Center for Biosustainability, Kgs. Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870) 
 Rigshospitalet, Department of Clinical Microbiology 9301, Copenhagen, Denmark (GRID:grid.475435.4) 
 CSIC, Centro Nacional de Biotecnología, Madrid, Spain (GRID:grid.428469.5) (ISNI:0000 0004 1794 1018) 
 CSIC, Centro Nacional de Biotecnología, Madrid, Spain (GRID:grid.428469.5) (ISNI:0000 0004 1794 1018); Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen Macarena, CSIC, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
 Rigshospitalet, Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen, Denmark (GRID:grid.475435.4) 
 Technical University of Denmark, The Novo Nordisk Foundation Center for Biosustainability, Kgs. Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870) 
 Rigshospitalet, Department of Clinical Microbiology 9301, Copenhagen, Denmark (GRID:grid.475435.4); University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
Pages
2584
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2973344014
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.